Two Demo Days Unite to Propel Startups onto the Global
Stage
Three Major Forums Highlight New Opportunities in Asian
Biotech
TAIPEI, April 21,
2025 /PRNewswire/ -- Co-organized by the
Biotechnology Innovation Organization (BIO) and the Taiwan Bio
Industry Organization (Taiwan BIO), BIO Asia–Taiwan
2025 will be held July 23-27 at
TaiNEX 1 & 2, Nangang Exhibition Center, Taipei. Building on last year's focus on
innovation, investment, and regional collaboration, the gathering
is expected to draw biotech professionals from more than 50
countries. The exhibition will feature over 900 leading companies
occupying 2,200+ booths. New to the program this year is the Demo
Day along with site visits to some of Taiwan's leading biomedical parks, extending
the overall program to nine days.
Liu Lee-Cheng, chairman of Taiwan
BIO, is pleased to reveal that the theme of this year's convention
is Next Wave of Biotech Opportunities.
The program will feature five major components:
- Conference Forum Series, including the Innovation Forum,
Investment Summit, and Regional Collaboration Forums.
- BIO Asia–Taiwan Exhibition
- BIO Partnering — one-on-one business matchmaking meetings
- Company Presentations
- Satellite Forums and Seminars
With a nod to the growing number of Taiwan biotech startups, the conference is
also partnering with two major local initiatives — the National
Biotechnology Research Park Demo
Day, and the TMU x BE x SCHS Demo Day — integrating them
into the program. The goal is to help Taiwan's biotech startups create international
collaboration opportunities through the BIO Asia–Taiwan
platform.
The National Biotechnology Research Park Demo Day has, to date, facilitated
nearly 100 matchmaking meetings with international pharmaceutical
companies and accelerators, as well as organizing talent
recruitment sessions. This year over 50 startup teams will be
invited to give team presentations, and selected teams will receive
value-added mentorship from the Park. The TMU x BE x SCHS Demo
Day will feature domestic and international teams, focusing on
artificial intelligence, digital health, and medical devices.
Chairman of BIO Asia–Taiwan Organizing Committee, Johnsee Lee,
stated that this year's Investment Summit, building on its
debut last year, will feature an expanded format with the National
Development Fund, Taiwan Stock Exchange, and TPEx providing support
and guidance. Organizers have invited biotech companies backed by
domestic and international venture capital firms to participate in
a selection process, ultimately selecting 30 firms from
Taiwan and abroad to deliver
company presentations to an audience of invited investment experts.
These include executives from multinational biotech and
pharmaceutical firms Amgen, AbbVie, Gilead, Novo Nordisk, Roche,
Novartis, AstraZeneca (AZ), Daiichi Sankyo, Illumina, and GE
Healthcare. In addition, investors from Syncona (UK), Genome
Capital (USA), and others have
been invited to explore opportunities.
The Regional Collaboration Forum, co-organized with the
Taiwan External Trade Development Council (TAITRA), has invited
Claire Skentelbery, Chair of the
International Council of Biotechnology Associations (ICBA), to give
the opening presentation. She will join representatives from
biotech associations in Japan,
the United States, Canada, Australia, Belgium, Thailand, and India to discuss topics such as biotech
investment, regulatory frameworks, and business collaboration
opportunities within various countries. Additionally, delegations
from Belgium and Thailand are planning official visits to
Taiwan to participate in the
occasion.
The Innovation Forum is co-organized by Academia Sinica,
National Health Research Institutes (NHRI), Bora
Pharmaceuticals, EirGenix, IRPMA (International Research-based
Pharmaceutical Manufacturers Association), Taiwan Bio-Manufacturing
Corporation (TBMC), Development Center for Biotechnology
(DCB), Industrial Technology Research Institute (ITRI), Taipei
Medical University, and the Taiwan Digital Health Industry
Development Association (TAIDHA).
Conference sessions will focus on current biotech industry
trends and the latest technological developments, and will feature
prominent international speakers. Highlights include:
Jens Juul Holst, discoverer of
GLP-1, leading to today's leading diabetes and obesity
treatments and a Tang Prize laureate, will deliver an in-depth
analysis of the revolutionary breakthroughs of GLP-1
in diabetes therapy.
George Hara, a UN ambassador,
impact investor, and BIO Asia Award 2024 winner, will share
insights on how the biotech industry can drive economic growth and
create social value.
My Linh Kha, Senior Vice
President of Amgen Japan and Asia
Pacific, will discuss the latest industry trends.
David Flores, President of
BioCentury, will explore biotech market strategies and investment
trends.
The BIO Asia–Taiwan Exhibition is nearly fully booked,
with over 900 companies participating, utilizing more than 2,200
booths. Themed zones include those focused on CDMO (Contract
Development and Manufacturing Organization), Pharmaceuticals and
Medical Devices, and Cell and Regenerative Medicine.
The CDMO Zone has attracted major domestic and
international companies, including Bora Pharmaceuticals, EirGenix,
Taiwan Bio-Manufacturing Corporation, Formosa Laboratories, Taimed
Biologics, Mycenax, TFBS Bioscience, Genovior Biotech, Amaran
Biotech, UBI Pharma, Zillion Fine Chemicals International, and
others.
In the Pharmaceuticals and Medical Devices Zone,
participating companies include PharmaEssentia, MycoMagic
Biotechnology, Golden Biotechnology, Foresee Pharmaceuticals, Wendy
International, Formosa Pharmaceuticals, AP Biosciences, TAHO
Pharmaceuticals, Charsire Biotechnology, Elixiron
Immunotherapeutics, BoYen Therapeutics, WCC Biomedical, Transin
Biomedical, Link-Best Bioscience, and others.
In the Cell and Regenerative Medicine Zone, participating
companies include Supercell Biotechnology, ChainHome Biotech,
Integrated Bio, Level Biotechnology, Mitek Lab, Han Biomedical,
Cold Spring Biotech, Omics Bio, Meribank Biotech, Only Science,
ACRO Biomedical, Purple Win International, StellaCell Bio, Cell-Bio
Biotechnology, and others.
Countries participating in the National Pavilions include
the United States, Australia, Belgium, Switzerland, Japan, India,
and Thailand. Multinational
companies such as Merck, BD, Cytiva, Fujifilm, Thermo Fisher, Genscript, Instem, and Panlabs
Biologics will also be exhibiting.
The BIO Asia–Taiwan Organizing Committee is certain that this
year's event will be exceptionally exciting. Currently, there are
only a few exhibition slots remaining. Early-bird discounts for the
conference forums and one-on-one partnering sessions are available
for registrations completed before June
20. Whether you're looking to exhibit, attend conference
forums and sessions, or participate in partnering meetings, be sure
to seize the opportunity and register quickly!
Event website: www.bioasiataiwan.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-asiataiwan-kicks-off-on-an-expanded-scale-july-23-302433351.html
SOURCE Taiwan Bio Industry Organization
